



What is claimed is:

1. A compound having the structure:



2. A crystal form comprising Compound B



having an X-ray powder diffraction pattern comprising peaks at 19.32, 20.26, 21.63, 23.28, or $24.81 \pm 0.1^\circ 2\theta$ ($\pm 0.1^\circ 2\theta$).


3. The crystal form of claim 2, wherein the crystal form of Compound B has an X-ray powder diffraction pattern one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty, characteristic X-ray powder diffraction peaks as set forth in Table 16.

4. The crystal form of claim 2, wherein the crystal form of Compound B has an X-ray powder diffraction pattern substantially as shown in FIG. 1.

5. The crystal form of any one of claims 2-4, wherein the crystal form of Compound B has a TGA thermograph corresponding substantially to the representative TGA thermogram as depicted in FIG. 2A.

6. The crystal form of any one of claims 2-5, wherein the crystal form of Compound B has a DSC thermogram substantially as depicted in FIG. 2B.

7. A crystal form comprising Compound B



having an X-ray powder diffraction pattern comprising peaks at 11.49, 12.54, 19.16, 19.42, or $24.67 \pm 0.1^\circ 2\theta$ ($\pm 0.1^\circ 2\theta$).


8. The crystal form of claim 7, wherein the crystal form of Compound B has an X-ray powder diffraction pattern one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty, characteristic X-ray powder diffraction peaks as set forth in Table 17.

9. The crystal form of claim 7, wherein the crystal form of Compound A has an X-ray powder diffraction pattern substantially as shown in FIG. 4.

10. The crystal form of any one of claims 7-9, wherein the crystal form of Compound A has a TGA thermograph corresponding substantially to the representative TGA thermogram as depicted in FIG. 5.

11. The crystal form of any one of claims 7-10, wherein the crystal form of Compound A has a DSC thermogram substantially as depicted in FIG. 5.

12. A crystal form comprising Compound B



B

having an X-ray powder diffraction pattern comprising peaks at 11.31, 15.70, 16.54, 19.10, or $22.76 \pm 0.1^\circ 2\theta$.


13. The crystal form of claim 12, wherein the crystal form of Compound B has an X-ray powder diffraction pattern one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty, characteristic X-ray powder diffraction peaks as set forth in Table 19.

14. The crystal form of claim 12, wherein the crystal form of Compound B has an X-ray powder diffraction pattern substantially as shown in FIG. 12.

15. The crystal form of any one of claims 12 to 14, wherein the crystal form of Compound B has a TGA thermograph corresponding substantially to the representative TGA thermogram as depicted in FIG. 13.

16. The crystal form of any one of claims 12 to 15, wherein the crystal form of Compound B has a DSC thermogram substantially as depicted in FIG. 13.

17. A crystal form comprising Compound B



B


having an X-ray powder diffraction pattern comprising peaks at 12.52, 15.90, 19.66, 20.65, or $24.99 \pm 0.1^\circ 2\theta$.

18. The crystal form of claim 17, wherein the crystal form of Compound B has an X-ray powder diffraction pattern one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty, characteristic X-ray powder diffraction peaks as set forth in Table 20.

19. The crystal form of claim 17, wherein the crystal form of Compound B has an X-ray powder diffraction pattern substantially as shown in FIG. 16.

20. The crystal form of any one of claims 17 to 19, wherein the crystal form of Compound B has a DSC thermogram substantially as depicted in FIG. 18.

21. A crystal form comprising Compound B



having an X-ray powder diffraction pattern comprising peaks at 11.46, 12.51, 19.29, 19.42, or $20.23 \pm 0.1^\circ 2\theta$.

22. The crystal form of claim 21, wherein the crystal form of Compound B has an X-ray powder diffraction pattern one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty, characteristic X-ray powder diffraction peaks as set forth in Table 21.

23. The crystal form of any one of claims 21 to 22, wherein the crystal form of Compound B has an X-ray powder diffraction pattern substantially as shown in FIG. 19.

24. The crystal form of any one of claims 21 to 23, wherein the crystal form of Compound A has a TGA thermograph corresponding substantially to the representative TGA thermogram as depicted in FIG. 20.

25. A pharmaceutical composition comprising the solid form of any one of claims 1 to 24 and at least one pharmaceutically acceptable excipient.


26. A compound of any one of claims 1 to 24 or the pharmaceutical composition of claim 25 for use in therapy.

27. Use of a compound of any one of claims 1 to 24 or the pharmaceutical composition of claim 25 in the manufacture of a medicament for treating lung cancer, ovarian cancer, endometrial cancer, prostate cancer, uterine cancer, or breast cancer in a patient having said cancer.


28. Use of a compound of any one of claims 1 to 24 or the pharmaceutical composition of claim 25 in the manufacture of a medicament for treating breast cancer in a breast cancer patient.

29. The use of claim 28, wherein said breast cancer is hormone receptor positive breast cancer, HER2-positive breast cancer or triple negative breast cancer.
30. The use of claim 28, wherein the breast cancer is metastatic breast cancer.
31. The use of any one of claims 28 to 30, wherein the compound or pharmaceutical composition is to be administered as a component of adjuvant therapy.
32. The use of any one of claims 28 to 30, wherein the compound or pharmaceutical composition is to be administered as a component of neoadjuvant therapy.
33. The use of any one of claims 28 to 32, wherein the breast cancer is stage 0, I, II, III, or IV.
34. The use of claim 29, wherein the hormone receptor positive breast cancer is HER2 negative.
35. The use of any one of claims 28 to 34, wherein the patient has had previous treatment with one or more anti-cancer agents or radiation therapy.
36. The use of any one of claims 28 to 35, wherein the patient has had surgery prior to treatment with a compound of any one of claims 1 to 24.
37. The use of any one of claims 28 to 36, wherein the compound of any one of claims 1 to 24 is to be administered in combination with one or more of radiation therapy, hormone therapy, or an anti-cancer agent.
38. The use of claim 37, wherein anti-cancer agent comprises one or more of doxorubicin, pegylated liposomal doxorubicin, epirubicin, paclitaxel, albumin-bound paclitaxel, docetaxel, 5-fluorouracil, cyclophosphamide, cisplatin, carboplatin, vinorelbine, capecitabine, gemcitabine, ixabepilone, eribulin, olaparib, methotrexate, anastrozole, exemestane, toremifene, letrozole, tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, trioxifene, keoxifene, ftutamide, nilutamide, bicalutamide, lapatinib, vinblastine, goserelin, leuprolide, pegfilgrastim, filgrastim, venetoclax.
39. The use of claim 37, wherein the anti-cancer agent comprises one or more of an AKT inhibitor, a CDK4/6 inhibitor, a PARP inhibitor, an aromatase inhibitor.
40. The use of claim 37, wherein the anti-cancer agent is abemaciclib, ribociclib, or palbociclib.


41. The use of claim 37, wherein the anti-cancer agent is ipatasertib.
42. The use of claim 37, wherein the anti-cancer agent is everolimus or fulvestrant.
43. The use of claim 37, wherein the anti-cancer agent is ado-trastuzumab emtansine, trastuzumab, pertuzumab, atezolizumab.
44. The use of claim 37, wherein the anti-cancer agent is alemtuzumab, bevacizumab, cetuximab, panitumumab, rituximab, tositumomab, or a combination thereof.
45. A process for the preparation of Compound B,




wherein the process comprises the steps of:




46. A process for the preparation of Compound B,




wherein the process comprises the steps of:



47. The process of claim 45 or 46, wherein the process further comprises recrystallization of Compound B in methanol and ethanol;



48. The process of claim 45 or 46, wherein the process further comprises recrystallization of Compound B in MTBE, water, NaOH and ethanol;



49. The process of any one of claims 45 to 48, wherein the indolyl intermediates are synthesized according to the steps:

